MichaelA.JamesRippeeMD

Sports Neurologist, Concussion expert, Medical Director for the Center for Concussion Management at The University of Kansas Health System Associate Professor, Neurology, University Kansas School of Medicine

Join to view full profile

Dr. Rippee is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rippee's full profile

Already have an account?

Office
3599 Rainbow Blvd
Kansas City, KS 66103

Education & Training

University of Kansas School of MedicineFellowship, Vascular Neurology, 2011 - 2012
University of Kansas School of MedicineResidency, Neurology, 2008 - 2011
University of Missouri Kansas City School of MedicineClass of 2007

Certifications & Licensure

KS State Medical License 2011 - 2025
American Board of Psychiatry and Neurology Neurology
American Board of Psychiatry and Neurology Vascular Neurology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Ghrelin (OXE--103) for Acute Concussion Management Start of enrollment: 2020 Oct 20
Completed
Phase 2

Publications & Presentations

PubMed

The Impact of Cognitive Behavioral Therapy for Insomnia on Neurofilament Light and Phosphorylated Tau in Individuals with a Concussion.
Rebecca Ludwig, Michael Rippee, Linda D'Silva, Jeff Radel, Aaron M Eakman
Archives of Clinical Neuropsychology. 2024-11-06
Evaluating olfactory function and quality of life in patients with traumatic brain injury.
Amelia S Lawrence, Rahul Alapati, Sarah F Wagoner, Antonio Bon Nieves, Cole Bird
International Forum of Allergy & Rhinology. 2024-08-01
2 citations
Assessing Cognitive Behavioral Therapy for Insomnia to Improve Sleep Outcomes in Individuals With a Concussion: Protocol for a Delayed Randomized Controlled Trial.
Rebecca Ludwig, Michael Rippee, Linda J D'Silva, Jeff Radel, Aaron M Eakman
JMIR Research Protocols. 2022-09-23

Press Mentions

Oxeia Announces Positive Interim Results of Phase 2 Trial for oxe103 for the Treatment of ConcussionsAugust 3rd, 2022
Symptoms You May Experience After Getting a COVID-19 VaccineJanuary 5th, 2021
Oxeia Biopharmaceuticals, Inc. Announces Initiation of Phase 2 Trial for OXE103 for the Treatment of ConcussionsOctober 21st, 2020
Join now to see all